drugset
drugset / Trial / NCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

NCT05473156 ↗

Phase 1/2 Recruiting 168 enrolled AP Biosciences Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities of AP203 in adult patients with locally advanced or metastatic solid tumors.

Timeline

Start
2023-07-24
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AP203 Unknown 0.00064 mg/kg Intravenous
Subject AP203 Unknown 20 mg/kg Intravenous

Indications

esophageal squamous cell carcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma